Abstract:The arrival of comprehensive genome sequencing has accelerated the understanding of genetically aberrant advanced cancers and target identification for possible cancer treatment. Fibroblast growth factor receptor (FGFR) gene alterations are frequent findings in various rare and advanced cancers refractive to mainstay chemo-therapy or surgical interventions. Several FGFR inhibitors have been developed for addressing these genetically altered FGFR-harboring malignancies, and some have performed well in clinical trials. In contrast, others are still being investigated in different phases of clinical trials. FDA has approved four anticancer agents such as erdafitinib, pemigatinib, infigratinib, and futibatinib, for clinical use in oncogenic FGFR-driven malignancies. These include cholangiocarcinoma, urothelial carcinoma, and myeloid/lymphoid malignancies. Pemigatinib is the only FGFR inhibitor globally approved (USA, EU, and Japan) and available as a targeted therapy for two types of cancer, including FGFR2 fusion or other rearrangements harboring cholangiocarcinoma and relapsed/refractory myeloid/lymphoid neoplasms with FGFR1 rearrangements. Myeloid/lymphoid neoplasm is the latest area of application added to the therapeutic armamentarium of FGFR inhibitors. Furthermore, futibatinib is the first-in-class covalent or irreversible pan-FGFR inhibitor that has received FDA approval for locally advanced or metastatic intrahepatic cholangiocarcinoma harboring FGFR2 gene aberrations. This review highlights the current clinical progress concerning the safety and efficacy of all the approved FGFR-TKIs (tyrosine kinase inhibitors) and their ongoing investigations in clinical trials for other oncogenic FGFR-driven malignancies.

Recent Advances in Tumor Therapy Targeting FGFR

Recent developments and advances of FGFR as a potential target in cancer

Targeting FGFRs for Tumor Therapy: Current Status and Novel Strategies

Targeting FGFR for cancer therapy

Recent advances of dual FGFR inhibitors as a novel therapy for cancer

Research Progress in the Mechanism of Molecular Targeted Anti-tumor Drugs

Recent Advance in the Development of Novel, Selective and Potent FGFR Inhibitors

Clinical advances and challenges in targeting FGF/FGFR signaling in lung cancer

Pharmacological and Biological Targeting of FGFR1 in Cancer

Molecular Targeting of the Fibroblast Growth Factor Receptor Pathway across Various Cancers

FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions

FGFR Families: Biological Functions and Therapeutic Interventions in Tumors

FGFR-TKI Resistance in Cancer: Current Status and Perspectives

A FGFR1 inhibitor patent review: progress since 2010

Advances of Fibroblast Growth Factor/Receptor Signaling Pathway in Hepatocellular Carcinoma and its Pharmacotherapeutic Targets

A comprehensive overview of selective and novel fibroblast growth factor receptor inhibitors as a potential anticancer modality

Advances in the treatment of tumors with focal adhesion kinase inhibitors

Advances in Anti-Tumor Therapy Targeting the EGFR Family of Receptor Tyrosine Kinases

Recent progress on vascular endothelial growth factor receptor inhibitors with dual targeting capabilities for tumor therapy

Advances In Combination Of Antiangiogenic Agents Targeting Vegf-Binding And Conventional Chemotherapy And Radiation For Cancer Treatment

Therapeutic implications of fibroblast growth factor receptor inhibitors in a combination regimen for solid tumors